Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 13

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 13
---
 name. We are currently focusing on development of the ADC Programs and plan to operate under a new name. We note that the License Agreement with WuXi Biologics is presently
in effect, and that Aadi has already paid a non-refundable $6 million upfront payment, and development efforts are already underway in respect of the ADC Programs. Following the completion of the Divestiture, the FYARRO Business will be owned
and operated by Kaken, and Aadi will have no interest in, and receive no income from, the FYARRO Business.

Will the Divestiture be a taxable transaction to me?

The Divestiture is entirely a corporate action. Our stockholders will not realize any gain or loss for U.S. federal income tax
purposes as a result of the Divestiture. See the section entitled “The Divestiture—Material U.S. Federal Income Tax Consequences of the Divestiture” beginning on page 72 of this proxy statement.

When is the Divestiture expected to be completed?

We are
working towards completing the Divestiture as soon as possible. We currently expect to complete the Divestiture as soon as all of the conditions to the Divestiture Agreement are satisfied or waived, including stockholder approval of the Divestiture
Proposal at the Special Meeting, which we currently anticipate will occur in the first half of 2025. However, the exact timing of completion of the Divestiture, if at all, cannot be predicted because the Divestiture is subject to the closing
conditions specified in the Divestiture Agreement.

- 7 -

Are there any risks related to the Divestiture?

Yes. You should carefully read the section entitled “Risks Related to the Pending Divestiture” beginning on page 34 of this proxy
statement.

Why is it important for me to vote?

The Divestiture Proposal will not be approved at the Special Meeting without the affirmative vote of a majority of the outstanding shares of capital stock of
Aadi. Therefore, any shares that are not voted will have the same effect as a vote “AGAINST” the Divestiture Proposal.

What will happen if Aadi stockholders do not approve the Divestiture at the Special Meeting?

If Aadi stockholders do not approve the Divestiture at the Special
Meeting (including any adjournment or postponement thereof, if applicable), the Divestiture will not be completed. If the Divestiture is not completed, the Divestiture Agreement